🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

New in #practicalRO: Combining Radiotherapy with Immune Checkpoint Inhibitors for the Management of Muscle-Invasive Bladder Cancer: A Comprehensive Systematic Review from the Y-ECI ROSC EORTC group. #radonc tinyurl.com/prolancia

Excited to be a part of this collaboration with friends and colleagues in Amsterdam. It isn't inspired entirely to advance SABR in place of surgery; instead, it is about identifying how often adrenalectomies end up with positive margins and local recurrence. The preliminary data

🔥 Game-Changer in Salvage RT: PSA-Guided Hormone Therapy OncoAlert 🎯 Objective: •Determine survival benefit of adding ADT to postoperative RT based on pre-RT PSA levels 🏥 Methods: •Meta-analysis of RCTs (n = 5 trials; RT ± ADT) •Short-course ADT (4–6 mo) vs long-course

Cardiac SBRT for Refractory VT STOPSTORM.eu consortium The arrhythmogenic substrate is identified & defined from electroanatomical maps Accurate transfer of the radiation target to the planning CT scan Standardized workflows for cardiac target definition and transfer

A newly published "review" article: 🔹️Fully funded and written with company support 🔹️Includes company employees as co-authors 🔹️Medical writing outsourced and paid for 🎗 Yet declares: "no conflicts of interest" 🫣And it's published in one of the highest-impact journals

Happy to introduce something different from classical curative or palliative radiotherapy: Strategic radiotherapy: a new proof of concept sciencedirect.com/science/articl… ESTRO Sapienza Università di Roma

I learned this week that SABR-COMET patient #1 recently passed away, more than 12 years after enrollment, with no recurrence since his original SABR. We initially treated him for a left adrenal met. It’s an interesting story… ⬇️⬇️⬇️

❗️ Important work for SCLC 1-10 brain mets -> SRS mOS 10.2 m Only 22% of patients needed salvage WBRT Median 2 brain mets ascopubs.org/doi/10.1200/JC…

If you are a physician posting #MedEd about radiation… SABR/SBRT not Cyberknife SRS not GammaKnife We are educating patients not selling machines, right? Right?

Headlines rarely tell the whole story. When pembrolizumab was first approved in advanced gastric and GEJ cancer, the approvals seemed broad: combinations with chemo, HER2-targeted therapy, first-line, later-line — PD-L1 status didn’t seem to matter. But as more data emerged,

Nothing disturbs me more than the glorification of stupidity. - Carl Sagan

"Ninguna nación puede permanecer libre cuando el estado tiene más influencia que la familia sobre el conocimiento y los valores transmitidos a los niños" Ron Paul 🇺🇸

Excited to share our experience (largest so far) using Boswellia for radiation necrosis with brain mets. ORR 60%, median duration 14 months. Amazing responses and a game changer for patients, I highly recommend you check it out!!! pubmed.ncbi.nlm.nih.gov/39993542/ redjournal.org/article/S0360-…

Are there any treatments for metastatic cancer with a lower adverse event rate? Puneeth Iyengar Stephen V Liu, MD

Want a Sunday morning reading with a sip of coffee? Here is one (in press) for #PCSM enthusiasts! sciencedirect.com/science/articl… Always grateful for the support and motivation from Daniel E Spratt even during tough times and Yilun Sun for teaching me new things every time!!

In high-risk prostate cancer, radiotherapy plus ADT significantly reduces the risk of distant metastasis compared to surgery-based approaches. However, post-metastasis survival does not differ between treatments. European Urology Oncology Daniel E Spratt OncoAlert Advanced Prostate Cancer Consensus Conference European Association of Urology (EAU)

In my mind the highest quality evidence we have of RT compared to RP for high risk prostate cancer. Findings are very consistent with Amar Kishan centres of excellence data from JAMA Open (I think it was 2019 🤔) Well done Soumyajit Roy (Soum) and team!

Expanding the #radonc toolkit for ☢️necrosis (RN) tx after SRS for functional disorders In this case report, Boswellia serrata resolved RN in a pt w/ steroid-refractory RN after SRS (80 Gy) for OCD Should Boswellia be a 1st line tx for RN after SRS? advancesradonc.org/article/S2452-…

4.1K likes & 169K views on this post...which fails to mention the patient was also receiving standard of care 1st line "big pharma" FOLFIRINOX chemotherapy (info buried in screenshotted email)🤦🏽‍♀️.